PARP1 and neoplasm: Indeed, the presence of a BRCA mutation is a clinically validated predictive biomarker of PARP inhibitor sensitivity (Moore et al., 2018), and this has led to widespread implementation of germline and tumor BRCA testing to identify patients likely to benefit from PARP inhibitors.